Published in Cancer Weekly, March 7th, 2006
According to recent research published in the Journal of Neuro-Oncology, "The type III variant of the epidermal growth factor receptor (EGFRvIII) mutation is present in 20-25% of patients with glioblastoma multiforme (GBM). EGFRvIII is not expressed in normal tissue and is therefore a suitable candidate antigen for dendritic cell (DC) based immunotherapy of GBM."
An-hua Wu and colleagues at the University of Minnesota and University of California-San Diego wrote, "To identify the antigenic epitopes that may serve...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.